.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04A_DrugsForTreatmentOfTuberculosis.J04AB03_Rifamycin.Rifamycin

Information

Rifamycin is an antibiotic belonging to the rifamycin group, used primarily for the treatment of tuberculosis and other bacterial infections caused by susceptible strains. It exerts its antibacterial action by inhibiting DNA-dependent RNA polymerase in susceptible organisms. Rifamycin preparations are approved and used clinically, with formulations for oral, intravenous, or local (e.g., intestinal) administration.

Pharmacokinetics

Pharmacokinetic parameters after a single oral dose of rifamycin SV in healthy adult volunteers.

References

1. Hoy, SM (2019). Rifamycin SV MMX. Clinical drug investigation 39(7) 691–697. DOI:10.1007/s40261-019-00808-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31172447

2. Scarpignato, C, & Pelosini, I (2005). Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 51 Suppl 1 36–66. DOI:10.1159/000081990 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15855748

3. Zheng, C, et al., & Gao, F (2017). Clinical and pharmacological hallmarks of rifapentine's use in diabetes patients with active and latent tuberculosis: do we know enough?. Drug design, development and therapy 11 2957–2968. DOI:10.2147/DDDT.S146506 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29066867

Revisions

• 06/2025 initial generated model